The investment bank upgraded the pharma stock to overweight from equal weight.
This cybersecurity stock has room to run following Claude Mythos Preview’s release, KeyBanc says
CrowdStrike is likely to see its shares rise as Mythos’ limited roll out acts as a catalyst for cybersecurity spending, according to Key Banc.
Apple goes for the ‘continuity candidate’ to replace Cook. What the CEO change means for investors
Apple’s surprise leadership announcement sent Wall Street reconsidering their expectations for the future of the technology titan.
Cash has been a better portfolio diversifier than Treasurys, Morningstar finds. Where to nab attractive yields
With Fed rate cuts on hold, these cash assets still have solid yields.
These are the earnings reports NYSE insider Jay Woods is watching this week
In a weekly video to CNBC PRO subscribers, Woods discussed what he’s watching in a market at records.
Tariff refunds begin on Monday. These retailers are due big paydays
U.S. importers, such as Walmart and Target, could be in line for billions in tariff refunds as the government launches its claims-filing portal on Monday.
Two underperforming pet stocks are showing signs of life, says Katie Stockton
Katie Stockton of Fairlead Strategies breaks down the charts on these two pet stocks.
Three psychedelics stocks surge after Trump executive order. Oppenheimer sees more upside ahead
Some psychedelic stocks can rally after the executive order on the use of the this type of drug for mental health, Oppenheimer said.
Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’
“For the most part, this is not a market that’s on sale,” Marks said Monday.
Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says
The bank’s research arm raised its rating on the stock to overweight from equal weight.